Avacta Therapeutics has announced new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase Ib trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase Ia part of the study. … Read More
Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC). AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More
Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. Read More
Avacta Group has dosed its first patient in the fifth cohort of the first-in-human Phase I trial (ALS-6000-101) of AVA6000 in solid tumours. This follows the approval of an amended clinical trial protocol by the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to allow for… Read More
DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview… Read More
Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial. Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour… Read More
Clinical stage oncology company Avacta Group has moved its Therapeutics division to a new headquarters at Scale Space in Imperial College’s White City Campus, London. DDW Multimedia Editor Megan Thomas attended the open day to learn more about the company’s intentions. In this video, she speaks… Read More
Clinical stage oncology company Avacta Group has moved its Therapeutics division to a new headquarters in London. The headquarters will be based at Scale Space in Imperial College’s White City Campus, London. Scale Space is part of the broader White City Innovation District. White City is currently… Read More
Avacta’s BAMS assay to detect the SARS-CoV-2 virus has been launched as a research kit by its partner Adeptrix and the assay has been presented by Bruker Scientific, a mass spectrometer manufacturer, in a new application note. The bead-assisted mass spectrometry (BAMS) assay uses the Affimer reagents specific to the… Read More
